Krystal Biotech saw its IBD SmartSelect Composite Rating jump to 98 Monday, up from 93 the day before.
The upgrade means the stock currently tops 98% of all other stocks in terms of key performance metrics and technical strength. The top-performing stocks tend to have a 95 or better grade as they start a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
Krystal Biotech broke out earlier, but has fallen back below the prior 189.97 entry from a consolidation. In the scenario where a stock breaks out then falls 7% or more below the entry price, it's considered a failed breakout. If that happens, it's best to wait for a new pattern to take shape.
Looking For The Best Stocks To Buy And Watch? Start Here
The stock has an 82 EPS Rating, meaning its recent quarterly and annual earnings growth is outpacing 82% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
In Q4, the company reported 407% earnings-per-share growth. Top line growth came in at 116%, down from 879% in the prior quarter.
Krystal Biotech holds the No. 1 rank among its peers in the Medical-Biomed/Biotech industry group. United Therapeutics and Catalyst Pharmaceuticals are also among the group's highest-rated stocks.
